Market Insights - Industry Research Report

Liver Disease Treatment Market

Liver Disease Treatment Market Analysis By Treatment Type (Antiviral Drugs, Immunosuppressants, Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, and Chemotherapy), By Disease Type (Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liver Disease (NAFLD), Cancer, Genetic Disorders and Others), and By Region – Global and Regional Industry Overview, Size, Share, Growth, Market Intelligence, Premium Insights, Comprehensive Analysis, Historical Data, and Forecasts 2023 – 2030

The Global Liver Disease Treatment Market Size Was Worth USD 21.43 Billion In 2022 And Is Estimated To Grow To USD 33.14 Billion By 2030, With A CAGR Of Approximately 5.6 % Over The Forecast Period From 2023 To 2030.

Liver Disease Treatment Market Overview

The liver is a crucial organ of the body that carries out important tasks like storing vitamins and nutrients, purging unwanted compounds from the blood, and preserving a proper chemical equilibrium in the body. Common liver ailments include cancer, hepatitis, autoimmune conditions, and genetic problems. Infections, heredity, obesity, diabetes, and immune system anomalies are the major causes of these illnesses. Vaccines, chemotherapy, antiviral medications, immunoglobulins, corticosteroids, and immunosuppressants are a few of the often utilized therapeutic approaches for liver illnesses. Treatment for liver disease aids in hormone and cholesterol excretion boosts bile synthesis and activates enzymes. The market is expected to rise due to the rising prevalence of fatty liver disease brought on by excessive cholesterol, obesity, hypertension, and diabetes. Additionally, several technological developments, such as the creation of the bioartificial liver, are accelerating market expansion. The quick uptake of antiviral medications is positively impacting the market growth due to their safety and efficacy, ability to suppress the hepatitis B virus, and ability to lower the risk of developing cirrhosis and hepatocellular carcinoma. A good picture of the market is also being created by rising research and development (R&D) efforts, significant healthcare sector growth, and numerous government initiatives to promote public health.

Market Drivers:

The excessive buildup of extra fat in the liver is a condition known as liver disease, particularly non-alcoholic fatty liver disease (NAFLD). In developing nations like India and China, NAFLD is becoming recognized as the primary contributor to chronic liver disease. As a result, government agencies are developing creative and appealing programs to combat liver illnesses. For instance, the Indian government stated in February 2021 that NAFLD would be incorporated into the National Program for Prevention & Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS). This program primarily focuses on several issues, such as the early diagnosis and management of NAFLD and the development of a healthcare system for the prevention, detection, and treatment of NAFLD. Such government actions could boost the market for treating liver disease within the anticipated time frame.

Restraints

The requirement for substantial expenditure in drug development may constrain the analysis period’s expansion of the global liver disease treatment market. In addition, strict government regulations by the U.S. Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA), as well as the side effects connected with medications, are some of the factors impeding the growth of the global market.

Liver Disease Treatment Market: Segmentation

The global liver disease treatment market is segregated based on treatment type and disease type.

  • Based on treatment type, the market is divided into antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. Among these, the antiviral drugs category led the market in 2021 and is expected to maintain its dominance throughout the forecast period. The antiviral drug sub-segment is benefiting from the significantly increasing investments in the field of antiviral pharmaceuticals, which is mostly due to its great benefits. The rise in healthcare spending increased public awareness, and the rising prevalence of hepatitis B and C are key factors expected to support market expansion. In addition, major industry participants are developing fresh technologies to expand their position globally.
  • Based on disease type, the market is divided into hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, and genetic disorders. The non-alcoholic fatty liver disease (NAFLD) category dominated the market in 2021. Some key drivers driving the sub-segment growth include the massive rise in obesity prevalence worldwide, liver disease awareness in developing nations, diabetes, and considerable R&D spending. Furthermore, the National Diabetes Statistics Report, 2020, issued by the CDC, states that roughly 34.2 million Americans have diabetes (10.5% of the US population), making it the seventh greatest cause of death in the nation. These crucial factors are also projected to fuel the market for NAFLD drugs.

Liver Disease Treatment Market: Regional Landscape

In 2022, the Asia Pacific dominated the market for liver disease treatment. The necessity for new healthcare infrastructure, increasing hepatitis cases, and hepatocellular carcinoma fuel market growth. Due to acceptable government actions regarding lowering medical costs and developing new drugs to treat liver disease, Japan and Australia are promoting the market growth. Market expansion in the area is fueled by the elements above. In India, around 10 lakh people receive a new diagnosis of liver cirrhosis each year. The rise in the number of people with diabetes and obese people in India has doubled in market growth.

COVID-19 Impact:

The COVID-19 outbreak is expected to have a moderate impact because of the fall in demand for certain medications used in liver treatments. Limited access to medical treatment, a staffing crisis in the healthcare industry, an increase in the number of hospitalizations connected to COVID-19, and the availability of medications and vaccines are additional issues that impact the market. However, as COVID-19 immunizations become available, several countries are attempting to guarantee an uninterrupted supply of medicines and vaccines that can save lives. As a result, it is anticipated that this will eventually cause the market to stabilize. On the other hand, research projects and initiatives by different researchers, businesses, and the government, including clinical trials for the efficacy and safety of the treatment of liver illness, increased the market for liver disease treatments.

Liver Disease Treatment Market: Competitive Landscape

Some of the main competitors dominating the global liver disease treatment market include– ABBVIE INC., ABBOTT LABORATORIES, ASTELLAS PHARMA INC., BRISTOL-MYERS SQUIBB, ELI LILLY AND COMPANY, EMERGENT BIOSOLUTIONS INC. (CANGENE BIOPHARMA), F. HOFFMANN-LA ROCHE AG, GILEAD SCIENCES, INC., MERCK & CO. INC, and VIATRIS INC.

Recent Developments:

  • January 2022: A partnership between Novartis and Alnylam was announced to research targeted therapies to improve liver function. They have decided to collaborate on the research and development of siRNA-based targeted therapeutics to regenerate functional liver cells in patients with advanced liver disease. The collaboration intends to develop liver-targeted therapy as an alternative to transplantation for patients with liver failure.
  • January 2019: For treating non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis, SciCann Therapeutics established a liver disease program at Tel Aviv University. The program’s main goal was to examine the effectiveness of SciCann’s line of proprietary, cannabinoid-based, anti-inflammatory combination products (NASH)

The Global Liver Disease Treatment Market is segmented as follows:

Liver Disease Treatment Market By Treatment Type Outlook (Revenue, USD Million, 2017 – 2030)

  1. Antiviral Drugs
  2. Immunosuppressants
  3. Vaccines
  4. Immunoglobulins
  5. Corticosteroids
  6. Targeted Therapy
  7. Chemotherapy

Liver Disease Treatment Market By Disease Type Outlook (Revenue, USD Million, 2017 – 2030)

  1. Hepatitis
  2. Autoimmune Diseases
  3. Non-alcoholic Fatty Liver Disease (NAFLD)
  4. Cancer
  5. Genetic Disorders
  6. Others

Liver Disease Treatment Market By Region Outlook (Revenue, USD Million, 2017 – 2030)

  1. North America
    • The U.S.
    • Canada
    • Mexico
  2. Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  3. Asia Pacific
    • China
    • Japan
    • India
    • New Zealand
    • Australia
    • South Korea
    • Southeast Asia
    • Rest of Southeast Asia
  4. The Middle East & Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Kuwait
    • South Africa
    • Rest of the Middle East & Africa
  5. Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
Liver Disease Treatment Market Report Scope
Report Attribute Details
Market Size Value in 2022 USD 21.43 billion
Revenue Forecast in 2030 USD 33.14 billion
Growth Rate CAGR of 5.6 % from 2023 to 2030
Base Year for Estimation 2022
Historical Data 2017 – 2022
Forecast Years 2023 – 2030
Quantitative Units Revenue in USD million and CAGR from 2023 to 2030
Report Coverage Revenue forecast, company ranking, Trends
competitive landscape, and growth factors
Segments Covered Treatment Type, Disease Type, and Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country Scope U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico and Others
Key Companies Profiled ABBVIE INC., ABBOTT LABORATORIES, ASTELLAS PHARMA INC., BRISTOL-MYERS SQUIBB, ELI LILLY AND COMPANY, EMERGENT BIOSOLUTIONS INC. (CANGENE BIOPHARMA), F. HOFFMANN-LA ROCHE AG, GILEAD SCIENCES, INC., MERCK & CO. INC, and VIATRIS INC.

Frequently Asked Questions

The market is expected to rise due to the rising prevalence of fatty liver disease brought on by excessive cholesterol, obesity, hypertension, and diabetes. Additionally, several technological developments, such as the creation of the bioartificial liver, are accelerating market expansion.
According to the report, the global liver disease treatment market size was worth USD 21.43 billion in 2022 and is estimated to grow to USD 33.14 billion by 2030, with a compound annual growth rate (CAGR) of approximately 5.6 % over the forecast period.
In 2022, the Asia Pacific dominated the market for liver disease treatment. The necessity for new healthcare infrastructure, increasing hepatitis cases, and hepatocellular carcinoma fuel market growth.
Some of the main competitors dominating the global liver disease treatment market include- ABBVIE INC., ABBOTT LABORATORIES, ASTELLAS PHARMA INC., BRISTOL-MYERS SQUIBB, ELI LILLY AND COMPANY, EMERGENT BIOSOLUTIONS INC. (CANGENE BIOPHARMA), F. HOFFMANN-LA ROCHE AG, GILEAD SCIENCES, INC., MERCK & CO. INC and VIATRIS INC.

Share

Get in Touch with Us